INOVIO PHARMACEUTICALS INC (NASDAQ:INO) Reports Q2 2025 Results: Revenue at $0.0, EPS Loss of $0.61 Amid 4.7% After-Hours Drop

INOVIO PHARMACEUTICALS INC (NASDAQ:INO) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $0.61. The figures were largely in line with analyst expectations, which had projected no revenue and an EPS loss of $0.6153. Despite the alignment with estimates, the stock fell nearly 4.7% in after-hours trading, suggesting investor disappointment or broader market skepticism about the company's near-term prospects.

Key Financial Takeaways

• Revenue: Reported $0.0, matching analyst estimates.
• EPS: Posted a loss of $0.61, slightly better than the estimated loss of $0.6153.
• Market Reaction: Shares dropped ~4.7% in after-hours trading despite meeting expectations.

Performance Context

The stock had shown modest gains in recent weeks, rising 0.7% over the past month and 4.2% in the last two weeks. However, the post-earnings decline indicates that investors may have been hoping for a more optimistic update on the company's pipeline or financial outlook.

Pipeline and Business Highlights

While the press release did not provide explicit forward guidance, INOVIO highlighted progress in its DNA medicine pipeline, including:

• INO-3107: Lead candidate for recurrent respiratory papillomatosis (RRP), a rare HPV-related disease.
• Other Candidates: Continued development of INO-3112 (HPV-related oropharyngeal cancer), VGX-3100 (cervical and anal HSIL), and INO-5401 (glioblastoma and BRCA1/2 mutation-related cancer prevention).

The absence of a revenue beat or significant clinical trial updates may have contributed to the muted market response. Analysts currently expect full-year 2025 revenue to remain at $0.0, with an estimated EPS loss of $2.05. For Q3 2025, projections stand at $0.0 revenue and an EPS loss of $0.50.

Looking Ahead

Investors will likely focus on upcoming clinical trial milestones and potential partnerships to gauge INOVIO’s ability to transition from a development-stage biotech to a revenue-generating entity. The company’s reliance on its CELLECTRA delivery technology and DNA-based therapies remains a key differentiator, but commercialization timelines remain uncertain.

For a deeper dive into INOVIO’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.